---
title: "Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence"
description: "Formulary evidence on Zipalertinib (CLN-081, TAS6417) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence. Covers REZILIENT1, REZILIENT3, REZILIENT2, and REZILIENT4. 69 evidence topics quoted from 27 sources."
canonical: "https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 REZILIENT1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Original phase 1/2a efficacy objective

> “Evaluate the overall response rate (ORR).”

Source: [Piotrowska et al. (2019)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-001-WCLC-Poster-2019-08-30.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Phase 1/2a data cutoff

> “Data cut-off 9 May 2022”

Source: [Cullinan Therapeutics ASCO oral presentation (2022)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN081-ASCO-Oral-Presentation-CLN-081.pdf)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### REZILIENT1: phase 1/2 development program, NCT04036682

> “a Phase 1/2 clinical trial of zipalertinib”

Source: [Taiho Oncology REZILIENT1 phase 2b primary endpoint announcement (2025)](https://www.taihooncology.com/us/news/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-received-prior-therapy/)

<a id="topic-3.1.1.3-2"></a>

###### Pivotal cohort design

> “phase 1/2, open-label, multicenter trial”

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Original phase 1/2a cohort-transition design

> “Simon-Two Stage design”

Source: [Piotrowska et al. (2019)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-001-WCLC-Poster-2019-08-30.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Performance status eligibility

> “ECOG PS 0 or 1”

Source: [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational monotherapy regimen

> “100 mg BID oral”

Source: [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using RECIST v1.1 Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoints and blinded central review

> “The primary endpoints were ORR and DOR as assessed by blinded independent central review (ICR) per RECIST v1.1.”

Source: [Taiho Oncology ASCO 2025 REZILIENT1 results announcement (2025)](https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/)

<a id="topic-3.1.1.6.1-2"></a>

###### Regulatory rationale for objective response

> “ORR is a direct measure of a drug antitumor activity”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Original phase 1/2a planned enrollment

> “Approximately 90 patients are planned.”

Source: [Piotrowska et al. (2019)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-001-WCLC-Poster-2019-08-30.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Pivotal analysis populations

| Population | Quoted description |
| --- | --- |
| Primary efficacy population | “Primary efficacy population (N=176)” |
| Safety population | “Safety population (N=244)” |

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Updated prior-amivantamab cohort: data cutoff and enrollment

> “At data cutoff on June 13, 2025, 84 patients were enrolled”

Source: [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Primary efficacy population: minimum follow-up requirement

> “~8 months of minimum follow-up before data cutoff”

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Pivotal safety population: treatment-related discontinuations, n (%)

> “20 (8.2)”

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Pivotal safety population: baseline characteristics

| Characteristic | Value |
| --- | --- |
| Median age, years (range) | “65 (31–86)” |
| Female participants, n (%) | “157 (64)” |

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Phase 1/2a results at the selected dose

> “At 100 mg BID: ORR 41%, mDOR >21 mos, mPFS 12 mos”

Source: [Cullinan Therapeutics ASCO oral presentation (2022)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN081-ASCO-Oral-Presentation-CLN-081.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### Pivotal overall efficacy population: response outcomes

| Endpoint | Value |
| --- | --- |
| Confirmed ORR, overall efficacy population | “35%” |
| Median DOR, months | “8.8” |

Source: [Taiho Oncology ASCO 2025 REZILIENT1 results announcement (2025)](https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/)

<a id="topic-3.1.1.8.3-3"></a>

###### Pivotal results: prior platinum-based chemotherapy only

> “In patients treated after prior platinum-based chemotherapy only (n=125), ORR was 40% with mDOR of 8.8 months.”

Source: [Taiho Oncology REZILIENT1 Journal of Clinical Oncology publication announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology/)

<a id="topic-3.1.1.8.3-4"></a>

###### Updated prior-amivantamab cohort: prior amivantamab only

> “In patients with prior amivantamab only (n=54), ORR was 31.5% with mDOR of 9.5 months, and the DCR was 87.0%.”

Source: [Taiho Oncology IASLC 2025 World Conference on Lung Cancer announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer/)

<a id="topic-3.1.1.8.3-5"></a>

###### Pivotal progression-free and overall survival

| Population | Endpoint | Result |
| --- | --- | --- |
| “Primary efficacy population (N=176)” | “Median PFS, months (95% CI)” | “9.4 (7.4–10.0)” |
|  | “12-month OS rate” | “69.3%” |

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

Additional sources: [Piotrowska et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40450572/); [Piotrowska et al. (2023)](https://cullinantherapeutics.com/publications/safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patients-with-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-exon-20-insertions-2023-jco/); [Piotrowska et al. (2021)](https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9077); [Journal of Clinical Oncology (2026)](https://ascopubs.org/doi/abs/10.1200/JCO-26-01931?af=R)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Pivotal results: treatment-related adverse events

> “The most common grade ≥3 TRAEs were anemia (7%), pneumonitis and rash (2.5% each), increased alanine aminotransferase, diarrhea, and decreased platelet count (2.0% each).”

Source: [Taiho Oncology ASCO 2025 REZILIENT1 results announcement (2025)](https://www.taihooncology.com/us/news/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology-to-present-positive-results-from-pivotal-phase-2b-rezilient1-trial-of-zipalertinib-at-asco-2025/)

<a id="topic-3.1.1.8.5-2"></a>

###### Pivotal safety population: grade ≥3 treatment-related adverse events, n (%)

> “72 (29.5)”

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="topic-3.1.1.8.5-3"></a>

###### Pivotal treatment-related deaths

| Population | Endpoint | Result |
| --- | --- | --- |
| “Safety population (N=244)” | “TRAE leading to death” | “2 (0.8)” |

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The trial is open-label. Its pivotal efficacy population included 176 participants with approximately 8 months of minimum follow-up, whereas 244 participants formed the safety population. Prior-treatment cohorts and the later 84-participant amivantamab cohort have different eligibility histories and follow-up cutoffs. Their response estimates should not be treated as randomized comparisons or as interchangeable analyses. The phase 1/2a results are an earlier analysis of the same development program.

Source: [Cullinan Therapeutics ASCO oral presentation (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN-081-ASCO-2025-Oral-Presentation.pdf); [Cullinan Therapeutics WCLC poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/2025-WCLC-REZILIENT1.pdf); [Taiho Oncology IASLC 2025 World Conference on Lung Cancer announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-at-the-iaslc-2025-world-conference-on-lung-cancer/); [Cullinan Therapeutics ASCO oral presentation (2022)](https://cullinantherapeutics.com/wp-content/uploads/2025/09/CLN081-ASCO-Oral-Presentation-CLN-081.pdf)

Additional sources: [Yao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41406405/); [Piotrowska and Yu (2026)](https://pubmed.ncbi.nlm.nih.gov/41406409/)

<a id="heading-3.1.2"></a>

#### 3.1.2 REZILIENT3

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Primary comparison

> “assess progression-free survival in the zipalertinib plus chemotherapy arm versus the chemotherapy arm”

Source: [Taiho Oncology REZILIENT3 primary endpoint announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-of-progression-free-survival-in-planned-interim-analysis-of-phase-3-rezilient3-trial-in-first-line-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Interim analysis announcement date

> “Aug. 12, 2026”

Source: [Taiho Oncology REZILIENT3 primary endpoint announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-of-progression-free-survival-in-planned-interim-analysis-of-phase-3-rezilient3-trial-in-first-line-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer/)

<a id="topic-3.1.2.2-2"></a>

###### WCLC presentation date

> “Session Date: Monday, September 14, 2026”

Source: [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Global randomized design

> “multicenter, randomized, controlled, open-label global trial”

Source: [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/)

<a id="topic-3.1.2.3-2"></a>

###### Randomization ratio

> “1:1”

Source: [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)

Additional sources: [Heymach et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39957151/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Disease and prior-treatment setting

> “previously untreated, locally advanced or metastatic non-squamous NSCLC”

Source: [Taiho Oncology REZILIENT3 primary endpoint announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-of-progression-free-survival-in-planned-interim-analysis-of-phase-3-rezilient3-trial-in-first-line-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer/)

<a id="topic-3.1.2.4-2"></a>

###### Permitted untreated CNS disease

> “untreated, asymptomatic brain metastases up to 2 cm”

Source: [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Experimental combination regimen

> “zipalertinib 100mg BID plus chemotherapy”

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="topic-3.1.2.5-2"></a>

###### Crossover after progression in the chemotherapy arm

> “could cross over to zipalertinib after disease progression”

Source: [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Randomized participants

| Population | Participants |
| --- | --- |
| Total randomized | “279” |
| Zipalertinib plus chemotherapy | “140” |
| Chemotherapy alone | “139” |

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Primary PFS assessment

> “blinded independent central review”

Source: [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html)

<a id="topic-3.1.2.7.2-2"></a>

###### Pre-planned interim analysis: number of PFS events

> “122”

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="topic-3.1.2.7.2-3"></a>

###### Formal intention-to-treat and safety analysis-set definitions

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline brain metastases

| Characteristic | Zipalertinib plus chemotherapy | Chemotherapy alone |
| --- | --- | --- |
| Participants with brain metastases | “31.4%” | “31.7%” |

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Earlier interim analysis announcement

> “met its primary endpoint of progression-free survival (PFS) at a planned interim analysis.”
> “The trial will continue to monitor efficacy and safety.”

Source: [Taiho Oncology REZILIENT3 primary endpoint announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-of-progression-free-survival-in-planned-interim-analysis-of-phase-3-rezilient3-trial-in-first-line-egfr-exon-20-insertion-mutation-non-small-cell-lung-cancer/)

<a id="topic-3.1.2.8.3-2"></a>

###### Interim efficacy results

| Endpoint | Zipalertinib plus chemotherapy | Chemotherapy alone |
| --- | --- | --- |
| Median PFS, months | “14.5” | “8.5” |
| Objective response rate | “65.0%” | “40.3%” |
| Median DOR, months | “14.2” | “9.9” |

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="topic-3.1.2.8.3-3"></a>

###### Interim time-to-event comparisons

| Analysis | Quoted value |
| --- | --- |
| PFS hazard ratio | “0.50” |
| PFS hazard ratio, 95% CI | “0.34-0.73” |
| PFS P value | “0.00015” |
| OS event maturity | “30%” |
| OS hazard ratio | “0.72” |
| OS hazard ratio, 95% CI | “0.42-1.23” |

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Grade ≥3 adverse events

| Endpoint | Zipalertinib plus chemotherapy | Chemotherapy alone |
| --- | --- | --- |
| Participants with grade ≥3 adverse events | “87.1%” | “54.4%” |

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Results are from a planned interim analysis. OS was 30% mature, and its 95% confidence interval included 1. The comparator was chemotherapy, not the amivantamab-containing combination recommended by ESMO. Open-label treatment and permitted crossover are additional considerations when interpreting subsequent outcomes.

Source: [Taiho Pharmaceutical (2026)](https://www.taiho.co.jp/en/release/2026/20260914.html); [Taiho Oncology REZILIENT3 presidential symposium announcement (2026)](https://www.taihooncology.com/us/news/zipalertinib-plus-chemotherapy-first-line-phase-3-rezilient3-trial-data-selected-for-presidential-symposium-presentation-at-the-iaslc-2026-world-conference-on-lung-cancer/); [IASLC (2026)](https://www.prnewswire.com/news-releases/zipalertinib-plus-chemotherapy-significantly-extends-progression-free-survival-in-first-line-egfr-exon-20-insertion-positive-nsclc-302877285.html); [ESMO (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11648200/)

<a id="heading-3.1.3"></a>

#### 3.1.3 REZILIENT2

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Study objective

> “evaluate the safety and efficacy of zipalertinib”

Source: [National Cancer Institute NCI-2023-10904](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10904)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Cohort C data cutoff

> “February 17, 2025”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Ongoing cohort trial

> “ongoing phase 2b REZILIENT2 trial”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Active CNS metastases: molecular population

> “EGFR exon 20 insertion (ex20ins)/Other Uncommon Mutations”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Cohort C dose and administration

> “100 mg orally twice daily”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using RECIST v1.1 Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Investigator-assessed systemic primary endpoint

> “ORR per RECIST v1.1”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Cohort C enrollment

| Population | Participants |
| --- | --- |
| Total enrolled | “32” |

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Cohort C response-evaluable populations

| Population | Participants |
| --- | --- |
| RANO-BM evaluable | “16” |
| RECIST v1.1 evaluable | “29” |

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Cohort C biomarker population

| Characteristic | Participants, n (%) |
| --- | --- |
| EGFR exon 20 insertion mutations among all 32 participants | “21 (66)” |

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Active CNS metastases: intracranial response

> “5/16 (31.3%) patients with measurable CNS disease had confirmed responses by RANO-BM criteria (including 1 intracranial CR)”

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="topic-3.1.3.8.3-2"></a>

###### Additional cohort C response results

| Endpoint | Value |
| --- | --- |
| Confirmed systemic responses, n/N (%) | “8/29 (27.6%)” |
| Median intracranial DOR, months | “8.1” |

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

Additional sources: [Udagawa et al. (2025)](https://www.sciencedirect.com/science/article/pii/S1556086425012109)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Active CNS metastases: safety

> “Treatment-related adverse events of grade 3 or higher occurred in 8 patients (25%)”
> “There was one death due to interstitial lung disease.”

Source: [Taiho Oncology ESMO Congress 2025 active brain metastases announcement (2025)](https://www.taihooncology.com/us/news/taiho-oncology-and-cullinan-therapeutics-present-data-on-zipalertinib-in-patients-with-nsclc-with-egfr-mutations-and-active-brain-metastases-at-the-esmo-congress-2025/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The cohort enrolled 32 participants, of whom 21 (66%) had EGFR exon 20 insertions. Systemic response was reported in 8 of 29 evaluable participants and intracranial response in 5 of 16. These are different analysis populations, and the pooled results are not restricted to exon 20 insertions. The ongoing phase 2b cohort does not provide a randomized treatment comparison.

Source: [Cullinan Therapeutics ESMO poster (2025)](https://cullinantherapeutics.com/wp-content/uploads/2025/10/REZILIENT2_Cohort-C_ESMO-2025.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 REZILIENT4

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Adjuvant treatment objective

> “stop cancer from coming back”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### UK research ethics opinion date

> “13 Nov 2025”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Adjuvant development phase

> “Phase 3”

Source: [ClinicalTrials.gov NCT07128199](https://clinicaltrials.gov/study/NCT07128199)

<a id="topic-3.1.4.3-2"></a>

###### Randomization, masking, and multicenter design

> “Randomized, Placebo-Controlled, Double-Blind, Multi-Center”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Adjuvant disease population

> “Pathologic (post-operative) Stage IB, IIA, IIB, or IIIA according to the AJCC 9th tumor nodes metastasis (TNM) staging system for lung cancer.”

Source: [ClinicalTrials.gov NCT07128199](https://clinicaltrials.gov/study/NCT07128199)

<a id="topic-3.1.4.4-2"></a>

###### Minimum enrollment age, years

> “About 360 people who are at least 18 years old can enroll in this study.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Adjuvant randomized comparison

> “Arm A: Zipalertinib twice daily (BID) monotherapy OR Arm B: Placebo BID monotherapy.”

Source: [ClinicalTrials.gov NCT07128199](https://clinicaltrials.gov/study/NCT07128199)

<a id="topic-3.1.4.5-2"></a>

###### Study-drug dose

> “All participants will receive either 100 milligrams of zipalertinib or placebo, orally as tablets, along with other cancer drugs, twice a day in a 21-day cycle.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="topic-3.1.4.5-3"></a>

###### Study-drug dosing frequency

> “twice a day”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="topic-3.1.4.5-4"></a>

###### Maximum total study-drug treatment duration

> “3 years”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Disease-free Survival as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Regulatory setting for disease-free survival endpoints

> “the adjuvant setting after definitive surgery or radiotherapy.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment, participants

> “360”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The report contains trial-design information, not results. Eligibility covers uncommon EGFR mutations rather than exon 20 insertions alone, and the planned enrollment is 360 participants. No efficacy or safety estimate can be drawn from these protocol details.

Source: [ClinicalTrials.gov NCT07128199](https://clinicaltrials.gov/study/NCT07128199); [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rezilient4/)

## Related pages
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Zipalertinib (CLN-081): EGFR exon 20 insertion-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economics.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
